Experts praise cooperative groups (e.g., Chartered, Stampede) for conducting large studies and preserving samples for future biomarker research. These publicly funded efforts can address fundamental clinical questions that industry-sponsored trials may not prioritize, ultimately advancing the field.

We possess millions of data points on interventions, but they are useless to AI models because they're trapped in thousands of disparate EMRs in varied formats. The challenge is not generating more data, but solving the human incentive and alignment problems required to create unified data registries.

The primary challenge holding back precision medicine is not a lack of data or innovation. Instead, it's the operational difficulty of integrating and interpreting complex, siloed information quickly enough to make it clinically actionable for individual patients. The focus must shift from accumulation to execution.

The primary barrier to AI in drug discovery is the lack of large, high-quality training datasets. The emergence of federated learning platforms, which protect raw data while collectively training models, is a critical and undersung development for advancing the field.

A lack of representation in genomic data has direct clinical consequences. A deep understanding of European genetics and a poor understanding of other groups has already manifested in less precise medical treatments for non-European populations, undermining the core promise of precision medicine.

Rather than forcing thousands of global hospitals to adopt uniform instruments or protocols, Sophia Genetics' platform is built to work across this complexity. This approach supports wider adoption and turns the challenge of diverse data sources into a strength for building robust, generalizable AI models.

The progress of AI in predicting cancer treatment is stalled not by algorithms, but by the data used to train them. Relying solely on static genetic data is insufficient. The critical missing piece is functional, contextual data showing how patient cells actually respond to drugs.

Sophia Genetics helped a hospital in India go from outsourcing tests to the US (with a 6-week delay) to performing them locally in under two weeks. This approach defines democratization not just as providing access, but as empowering local institutions to build their own knowledge and capabilities.

Frontier AI models excel in medicine less because of their encyclopedic knowledge and more because of their ability to integrate huge amounts of context. They can synthesize a patient's entire medical history with the latest research—a task difficult for any single human. This highlights that the key to unlocking AI's value is feeding it comprehensive data, as context is the primary driver of superhuman performance.